rethinkPeptides Search
Menu
Study breakdown

Counterfeit Peptide Drugs Sold Online Contained Arsenic, Lead, and as Little as 5% Purity

evidence
The takeaway

Analysis of the 10 most common falsified peptide drugs on the Belgian black market found purity as low as 5%, arsenic concentrations up to 10x the safety limit, and lead contamination — exposing serious health risks for users.

5-75% purity range

Counterfeit injectable peptide drugs contained as little as 5% of the intended active ingredient, with the remainder being impurities, contaminants, and toxic metals

What the researchers found

Systematic screening of the 10 most frequently falsified peptide drugs from three suspected illegal internet pharmacies revealed:

Purity: ranged between 5% and 75% for cysteine-containing peptides — meaning up to 95% of some products were impurities rather than the intended drug

Elemental impurities:

- Multiple samples contained arsenic (As) at concentrations up to 10x the ICH toxicity limit for parenteral (injectable) drugs

- All arsenic was present in the more toxic inorganic form (confirmed by speciation analysis)

- One sample was contaminated with lead (Pb)

Other concerns: high variation in drug amount per unit, significant peptide-related impurities, and the presence of residual solvents from manufacturing

The study also flagged the inherent danger of some products being doping peptides or preclinical drugs not approved for human use.

Why it matters

The black market for peptide drugs is booming — driven by demand for research peptides, performance-enhancing compounds, and medications that are expensive through legitimate channels. Because these products are injected directly into the body, contamination with toxic metals like arsenic and lead is far more dangerous than in oral supplements. The finding of a known carcinogen at 10x safety limits in injectable products represents a genuine public health hazard, especially given that many users self-administer these peptides regularly over long periods.

How the study worked

The ten most frequently encountered falsified peptide drugs were acquired from three different suspected illegal internet pharmacies on the Belgian market. Systematic screening incorporated five analytical dimensions: active pharmaceutical ingredient (API) content, API-related impurities, small molecule contaminants, elemental impurity analysis (including arsenic and lead), and residual solvent analysis. Arsenic speciation was performed to determine whether arsenic was in its more toxic inorganic form or less toxic organic form.

What this study cannot tell us

The study examined products from the Belgian market, and contamination profiles may differ in other countries. Only three online sources were sampled. The specific peptide drug names are not listed in the abstract, limiting the ability to advise on specific products. The study assesses chemical contamination but does not report biological contamination (bacterial endotoxins, viruses) that could also pose risks in injectable products. Long-term health outcomes in users of these contaminated products are not tracked.

How to read the evidence

This is an analytical chemistry study with rigorous methodology (multi-dimensional impurity profiling, arsenic speciation). The evidence for contamination is direct and quantitative. However, it examines a limited sample from one market and does not include health outcome data from users.

When this study was published

Published in 2018, this study remains highly relevant as the online peptide market has grown significantly since. The contamination risks it identifies are likely unchanged or worsened as demand has increased without corresponding regulatory enforcement.

The bigger picture

The peptide drug black market has grown rapidly with the popularity of research peptides, growth hormone secretagogues, and anti-aging compounds. While pharmaceutical-grade peptides undergo rigorous quality control, counterfeit versions are manufactured in unregulated facilities — often in countries with minimal oversight — and sold directly to consumers online. This study provides some of the first systematic evidence of what's actually in these products, and the results are deeply concerning. As legitimate peptide therapeutics become more mainstream (GLP-1 agonists, antimicrobial peptides), the incentive to produce and sell counterfeits will only grow.

Questions still open

  • How many people worldwide are injecting contaminated peptide drugs purchased from unregulated online sources?
  • Could regulatory agencies do more to intercept counterfeit peptide shipments and shut down illegal online pharmacies?
  • Are users of counterfeit peptide drugs at risk for chronic arsenic or lead toxicity, given that these metals accumulate in tissues over time?

Common questions

Why is arsenic in injectable peptide drugs so dangerous?
Arsenic is a known carcinogen that accumulates in the body over time, damaging the liver, kidneys, nervous system, and skin. When it's in injectable drugs, it bypasses the body's first line of defense (the gut and liver) and enters the bloodstream directly. The study found all arsenic was in its most toxic inorganic form, at levels up to 10 times what international safety standards allow for injectable drugs. Regular users of these contaminated products could develop chronic arsenic poisoning without realizing the source.
How can consumers tell if a peptide product is counterfeit?
Unfortunately, it's nearly impossible for consumers to tell by looking at the product. Counterfeit peptides often come in professional-looking vials with convincing labeling. The only reliable protection is purchasing from licensed pharmacies with legitimate pharmaceutical supply chains. Products sold through unregulated websites, especially at significantly lower prices than pharmaceutical-grade versions, carry substantial contamination risk. This study shows that even products that look legitimate can contain dangerous levels of toxic metals.

Read the original research

Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market.

Talanta, 188, 795-807

Citation

Janvier, Steven; Cheyns, Karlien; Canfyn, Michaël; Goscinny, Séverine; De Spiegeleer, Bart; Vanhee, Celine; Deconinck, Eric. (2018). Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market.. Talanta, 188, 795-807. https://doi.org/10.1016/j.talanta.2018.06.023